Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Transthyretin amyloid depleter antibody - BridgeBio Pharma

Next Previous
Drug Profile

Research programme: Transthyretin amyloid depleter antibody - BridgeBio Pharma

Alternative Names: ATTR-CM depleter programme - BridgeBio Pharma; Evanesco; Transthyretin amyloid depleter antibody; TTR amyloid depleter; TTR amyloid depleter antibody

Latest Information Update: 12 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BridgeBio Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Amyloid modulators; Phagocyte stimulants; Prealbumin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Transthyretin-related hereditary amyloidosis

Most Recent Events

  • 25 Feb 2026 Preclinical trials in Transthyretin-related hereditary amyloidosis in USA (Parenteral) before February 2026
  • 25 Feb 2026 BridgeBio Pharma announces intention to submit IND to the US FDA in 2027
  • 25 Jan 2026 Early research in Transthyretin-related hereditary amyloidosis in USA (Parenteral), before January 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top